Deepa Anbazhagan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deepa Anbazhagan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Meram Azzani
Department of Public Health Medicine, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
3 shared publications - Lubna Shirin
Department of Anatomy, Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh 47000, Selangor, Malaysia
2 shared publications - Sabah Mohamed Alharazy
Early Clinical Exposure and Professional Personal Development, Faculty of Medicine, MAHSA University, Jenjarom 42610, Selangor, Malaysia
2 shared publications - Amal Shediwah
Department of Pathology, College of Medicine, Najran University, Najran 61441, Saudi Arabia
1 shared publication - Arutchelvan Rajamanikam
Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
1 shared publication - Barani Karikalan
Department of Pathology, Faculty of Medicine, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Selangor, Malaysia
1 shared publication
Latest Publications
- Open Access
- 28 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2016
The Association Between Cancer Incidence and Heart Failure: A Systematic Review and Meta-Analysis
Background/Objectives: Heart failure (HF) and cancers share common molecular and pathophysiological mechanisms. However, the association between HF and the risk of developing cancer remains unclear. This systematic review and meta-analysis evaluates the association between HF and the risk of cancer incidence by pooling data from studies that compared cancer incidence in HF patients with non-HF controls. Additionally, it quantifies pooled hazard ratios (HRs) for site-specific cancers. Methods: A systematic literature search was conducted across four databases until March 2025 (PROSPERO: CRD420251001541). Seven studies involving over 1.6 million participants were included. Three studies provided direct HF versus non-HF comparisons. Pooled HRs and their corresponding 95% confidence intervals (CIs) were calculated utilising random-effects models. Results: The pooled estimate for overall cancer in HF was not significant (HR 1.32; 95% CI: 0.94–1.85; p = 0.11). However, site-specific analyses revealed significantly elevated risks for lung cancer (HR 1.66; 95% CI: 1.27–2.16), urinary tract cancers (HR 1.66; 95% CI: 1.51–1.82), haematological cancers (HR 1.47; 95% CI: 1.12–1.94), and colorectal cancer (HR 1.38; 95% CI: 1.04–1.83). The associations with breast and prostate cancers were not significant. Notably, substantial heterogeneity was observed across most cancer sites (I2 = 96–98%), apart from urinary tract cancers (I2 = 0%). Conclusions: Although the pooled estimate for overall cancer was not significant, the significant findings for specific cancer sites suggest the need for enhanced cancer surveillance in patients with HF. Future research should focus on standardising definitions of HF, ensuring consistent adjustment for confounders, and stratifying data by HF phenotype.
- 28 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2016
Open AccessThe Association Between Cancer Incidence and Heart Failure: A Systematic Review and Meta-Analysis
Background/Objectives: Heart failure (HF) and cancers share common molecular and pathophysiological mechanisms. However, the association between HF and the risk of developing cancer remains unclear. This systematic review and meta-analysis evaluates the association between HF and the risk of cancer incidence by pooling data from studies that compared cancer incidence in HF patients with non-HF controls. Additionally, it quantifies pooled hazard ratios (HRs) for site-specific cancers. Methods: A systematic literature search was conducted across four databases until March 2025 (PROSPERO: CRD420251001541). Seven studies involving over 1.6 million participants were included. Three studies provided direct HF versus non-HF comparisons. Pooled HRs and their corresponding 95% confidence intervals (CIs) were calculated utilising random-effects models. Results: The pooled estimate for overall cancer in HF was not significant (HR 1.32; 95% CI: 0.94–1.85; p = 0.11). However, site-specific analyses revealed significantly elevated risks for lung cancer (HR 1.66; 95% CI: 1.27–2.16), urinary tract cancers (HR 1.66; 95% CI: 1.51–1.82), haematological cancers (HR 1.47; 95% CI: 1.12–1.94), and colorectal cancer (HR 1.38; 95% CI: 1.04–1.83). The associations with breast and prostate cancers were not significant. Notably, substantial heterogeneity was observed across most cancer sites (I2 = 96–98%), apart from urinary tract cancers (I2 = 0%). Conclusions: Although the pooled estimate for overall cancer was not significant, the significant findings for specific cancer sites suggest the need for enhanced cancer surveillance in patients with HF. Future research should focus on standardising definitions of HF, ensuring consistent adjustment for confounders, and stratifying data by HF phenotype.
- 24 March 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 588, 120977
Neutrophil gelatinase-associated lipocalin in contrast-induced acute kidney injury post cardiac procedure: a systematic review
- 24 March 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 588, 120977
Neutrophil gelatinase-associated lipocalin in contrast-induced acute kidney injury post cardiac procedure: a systematic review
- Open Access
- 15 August 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (8) , 415
Systematic Review and Meta-Analysis: Epidemiology of Human Blastocystis spp. Infection in Malaysia
Blastocystis spp. is a unicellular enteric protozoan parasite in humans with a controversial role in disease etiology. It is common in developing countries among immunocompromised patients and people who have close contact with animals. In this study, we have systematically reviewed previous studies on the distribution and genotypes of human Blastocystis infection in Peninsular Malaysia. Studies examining the prevalence of Blastocystis in diverse demographics, including rural, urban, comorbid conditions, and high-risk populations, were taken into consideration. The infection has been reported in nine states; the total percentage of infection was 17.8% (1671/9397), with the most cases in Pahang (27.3%) and the least in Johor (3.4%). Molecular studies revealed the presence of six subtypes: ST1, ST2, ST3, ST4, ST5, and ST6. ST3 was reported as the predominant subtype in all the states, with a prevalence of 54.7% (338/618). The findings provide greater clarity on the epidemiology of Blastocystis in Malaysia, which will help in policy making towards planning and strategizing control measures against the parasite.
- 15 August 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (8) , 415
Open AccessSystematic Review and Meta-Analysis: Epidemiology of Human Blastocystis spp. Infection in Malaysia
Blastocystis spp. is a unicellular enteric protozoan parasite in humans with a controversial role in disease etiology. It is common in developing countries among immunocompromised patients and people who have close contact with animals. In this study, we have systematically reviewed previous studies on the distribution and genotypes of human Blastocystis infection in Peninsular Malaysia. Studies examining the prevalence of Blastocystis in diverse demographics, including rural, urban, comorbid conditions, and high-risk populations, were taken into consideration. The infection has been reported in nine states; the total percentage of infection was 17.8% (1671/9397), with the most cases in Pahang (27.3%) and the least in Johor (3.4%). Molecular studies revealed the presence of six subtypes: ST1, ST2, ST3, ST4, ST5, and ST6. ST3 was reported as the predominant subtype in all the states, with a prevalence of 54.7% (338/618). The findings provide greater clarity on the epidemiology of Blastocystis in Malaysia, which will help in policy making towards planning and strategizing control measures against the parasite.